IGRA prevalence study
A cross-sectional study to determine IGRA positivity rate to assess eligibility for participation in tuberculosis (TB) vaccine efficacy trials
Quantitative
TB vaccine advocacy and acceptance in South Africa
Gathering a range of perspectives to provide early-stage insights into TB vaccine advocacy and acceptance in South Africa
Epidemiologic study to assess the IGRA positivity in populations with a high TB
Tuberculosis (TB) vaccine efficacy trials evaluating prevention of disease must be feasible in size and duration and would ideally take place at clinical trial sites that enroll from communities with the highest incidence rates. In preparation for the Phase 3 trial of the investigational M72/AS01E-4 vaccine, we conducted a multi-country study, using interferon gamma release assay (IGRA) positivity as a proxy for expected incidence of TB. In addition to the above objects, the results from this study could help in in new vaccine introduction to identfy TB hotspot areas.
Formative work to understand factors affecting future TB vaccines acceptance and readiness
This project aims to collect data to: 1) Assess health facility and health systems readiness for a new TB vaccine, and 2) Explore decision-making factors for new TB vaccine demand and acceptance
ACEITar: Evaluation of the acceptability of new and repurposed tuberculosis vaccines in Mozambique
This is a mixed-methods study collecting information on willingness to receive a new TB vaccine among adolescents, their caretakers, and adults in Mozambique, a high TB burden country, to assess potential barriers to high uptake of new TB vaccines.
Country and target population prioritization
Evidence-based matrixing approach to identify priority countries and target populations through an iterative process, engaging a set of diverse stakeholders
What do people want?
Investigate current TB prevention modalities vs vaccine. We lack understanding of preferences and trade offs people would be willing to make across a spectrum of issues related to study design, type of vaccines, how they are given, how often, where they are given, to whom, efficacy estimates and side effects etc.